julia.endo said:The pharmacokinetics explain nearly every practical question asked here.
Pushing back on julia.endo here. The counter-case has not been addressed. Somebody upthread described the situation that does not fit, and the thread moved on rather than engaging with it, which is the failure mode this board is supposed to avoid.
The figures, for anyone assembling their own picture. Numbers worth memorising for this class: Tmax one to three days for the weekly peptides, terminal half-life about a week for semaglutide and about five days for tirzepatide, steady state at four to five half-lives, subcutaneous bioavailability high enough that site choice is irrelevant.
JennaRN said:Somebody upthread described the situation that does not fit, and the thread moved on rather than engaging with it, which is the failure mode this…
Adding the part of the answer the thread has not reached. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.
I would rather be corrected than agreed with, if it comes to it.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOne thing that is still open after SandraNC_45’s answer:
Which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working?
OP back with an update, since a thread like this is useless without one.
Closing this out: the trough rather than the peak explains the pattern I was seeing on day six, which I had been blaming on the vial.